Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Neoplasms 2Skin Neoplasms 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1Leukemia 1Hematologic Diseases 1Bronchiolitis Obliterans Syndrome 1

Interventions

ibrutinib 3ruxolitinib 2asciminib 2Alemtuzumab 2sodium luminolate 1posaconazole 1ponatinib 1pegfilgrastim 1ofatumumab 1nilotinib 1montelukast 1mocetinostat 1lonafarnib 1ixekizumab 1fludarabine 1bosutinib 1belumosudil 1baricitinib 1axatilimab 1Voriconazole 1Tomography, X-Ray Computed 1Sofosbuvir 1Saline Solution 1SLC25A33 protein, human 1Rituximab 1Ribavirin 1Respiratory Function Tests 1Prednisone 1Pentostatin 1Oxycodone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Bronchiolitis Obliterans Syndrome × B3(Fv)-PE38KDEL recombinant immunotoxin × Clear all
NCT00077922 2018-01-23

Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
15 enrolled 10 charts
LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Diseases, Leukemia, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡